CAMBRIDGE, Mass., May 17, 2018 /PRNewswire/ -- Blueprint
Medicines Corporation (NASDAQ: BPMC), a leader in discovering
and developing targeted kinase medicines for patients with
genomically defined diseases, today announced two data
presentations supporting plans for rapid development of
avapritinib, a selective KIT and PDGFRα inhibitor, in patients with
gastrointestinal stromal tumors (GIST) and systemic mastocytosis
(SM).
Data from a retrospective natural history study of previously
treated patients with advanced PDPGFRα D842V-driven GIST will be
presented in a poster session at the 2018 American Society of
Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois on June 1-5, 2018. In addition, updated data from
Blueprint Medicines' Phase 1 EXPLORER trial of avapritinib in
patients with advanced SM will be presented in a poster session at
the 23rd Congress of the European Hematology Association
(EHA) in Stockholm, Sweden on
June 14-17, 2018.
The accepted abstracts are listed below and are now available
online on the ASCO and EHA conference websites, respectively:
https://am.asco.org/ and
https://ehaweb.org/congress/23rd-c/key-information/.
2018 American Society of Clinical Oncology (ASCO) Annual
Meeting
Presentation Title: A retrospective natural history study
of patients (pts) with PDGFRα D842V mutant advances
gastrointestinal stromal tumor (GIST) previously treated with a
tyrosine kinase inhibitor (TKI)
Session Title: Sarcoma
Session Date & Time: Saturday,
June 2, 2018 from 8:00 a.m. –
11:30 a.m. CT (9:00 a.m. – 12:30 p.m.
ET)
Abstract Number: 11533
Poster Board Number: 278
Location: Hall A, McCormick Place
23rd Congress of the European Hematology Association
(EHA)
Presentation Title: Avapritinib (BLU-285), a Selective
KIT Inhibitor, is Associated with High Response Rate and Tolerable
Safety Profile in Advanced Systemic Mastocytosis (AdvSM): Results
of a Phase 1 Study
Session Title: Myeloproliferative neoplasms - Clinical
Session Date & Time: Friday, June
15, 2018 from 17:30 – 19:00
CEST (11:30 a.m. –
1:00 p.m. ET)
Abstract Number: PF612
Location: Poster Area, Stockholmsmässan
About Blueprint Medicines
Blueprint Medicines is developing a new generation of
targeted and potent kinase medicines to improve the lives of
patients with genomically defined diseases. Its approach is rooted
in a deep understanding of the genetic blueprint of cancer and
other disease driven by the abnormal activation of kinases.
Blueprint Medicines is advancing multiple programs in clinical
development for subsets of patients with gastrointestinal stromal
tumors, hepatocellular carcinoma, systemic mastocytosis, non-small
cell lung cancer, medullary thyroid cancer and other advanced solid
tumors, as well as multiple programs in research and preclinical
development. For more information, please
visit www.blueprintmedicines.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-announces-data-presentations-at-upcoming-asco-and-eha-meetings-supporting-plans-for-rapid-development-of-avapritinib-in-patients-with-gastrointestinal-stromal-tumors-and-systemic-mastocytosis-300650273.html
SOURCE Blueprint Medicines